“The Buzz” Show: Curis, Inc. (NASDAQ: CRIS) Surges Upon Positive Leukemia Treatment Trial Results | Financial Buzz

“The Buzz” Show: Curis, Inc. (NASDAQ: CRIS) Surges Upon Positive Leukemia Treatment Trial Results

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Curis, Inc. Surges Upon Positive Leukemia Treatment Trial Results”

Curis, Inc. (NASDAQ: CRIS) surged over 279% in premarket trading after announcing a positive preliminary data from its ongoing open-label, single arm Phase 1 dose escalation study of CA-4948.

The novel, small molecule IRAK4 kinase inhibitor plays an essential role in the toll-like receptor and interleukin-1 receptor signaling pathways, which are frequently dysregulated in patients with AML and MDS.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin’s lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

For more information, please visit: Curis, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.